Media coverage about Applied Genetic Technologies (NASDAQ:AGTC) has trended somewhat positive on Thursday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.166967242036 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Applied Genetic Technologies Co. (AGTC) Expected to Announce Quarterly Sales of $6.21 Million (americanbankingnews.com)
- AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa (finance.yahoo.com)
- Zacks: Analysts Expect Applied Genetic Technologies Co. (AGTC) to Post -$0.25 Earnings Per Share (americanbankingnews.com)
- Global and United States Age Related Macular Degeneration Drug Market Application, Product, Sales and Forecast … (journalhealthcare.com)
- Global Adrenoleukodystrophy Drugs Market Outlook 2018-2023 : Applied Genetic Technologies Corp, Bluebird Bio Inc … (journalhealthcare.com)
Several brokerages have recently weighed in on AGTC. Zacks Investment Research upgraded Applied Genetic Technologies from a “sell” rating to a “hold” rating in a report on Friday, March 30th. ValuEngine cut Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Wedbush restated an “outperform” rating on shares of Applied Genetic Technologies in a report on Friday, February 9th. HC Wainwright set a $8.00 target price on Applied Genetic Technologies and gave the stock a “buy” rating in a report on Friday, February 9th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $9.00 target price on shares of Applied Genetic Technologies in a report on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $9.00.
Applied Genetic Technologies (NASDAQ:AGTC) last released its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.20). Applied Genetic Technologies had a negative net margin of 33.24% and a negative return on equity of 9.21%. The business had revenue of $4.85 million during the quarter, compared to analyst estimates of $8.72 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The company’s revenue was down 55.5% on a year-over-year basis. equities analysts predict that Applied Genetic Technologies will post -1.3 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Applied Genetic Technologies (AGTC) Getting Somewhat Favorable News Coverage, Accern Reports” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/04/19/applied-genetic-technologies-agtc-getting-somewhat-favorable-news-coverage-accern-reports.html.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.